Baxter International (NYSE:BAX) surged over 8% intra-day today after delivering better-than-expected fourth-quarter results, driven by strong sales in its Pharmaceuticals and Medical Products & Therapies divisions.
For Q4, the medical technology company posted adjusted earnings per share of $0.58, exceeding the $0.52 consensus estimate. Revenue reached $2.75 billion, beating forecasts of $2.67 billion and marking a 1% year-over-year increase on a reported basis and 2% growth at constant currency.
The Pharmaceuticals segment led the quarter’s strength, with high single-digit sales growth, while Medical Products & Therapies remained stable at reported rates but saw low single-digit growth on a constant currency basis. Management highlighted momentum in achieving strategic milestones as the company continues its push for enhanced value across healthcare sectors.
For the full year 2024, Baxter generated $10.64 billion in sales from continuing operations, reflecting 3% growth both on a reported and constant currency basis. Adjusted EPS for the year came in at $1.89.
Looking ahead, Baxter provided a confident 2025 outlook, projecting Q1 adjusted EPS between $0.47 and $0.50. For the full year, the company expects EPS in the range of $2.45 to $2.55, with sales growth of 5-6%.